MedTrace Logo

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

NCT05637580 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2022-12-05

No results posted yet for this study

Summary

This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.

Conditions

  • Non Small Cell Lung Cancer
  • Immunotherapy
  • Chemotherapy
  • Tumour, Residual

Interventions

DRUG

Timing of drug administration

The effect of drug administration timing on tumor and lymph node responses was observed.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Guibin Qiao, MD · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2022-07-01
Completion
2022-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05637580 on ClinicalTrials.gov